Opinion|Videos|January 2, 2024
ASH 2023 Updates on Frontline Therapies in FL
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.
Advertisement
Episodes in this series
Advertisement
Related to this article
Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
2
FDA Grants Fast Track Designation to Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma
3
FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
MOMENTUM Trial Aims to Add Further Evidence for Cemsidomide in R/R Myeloma
5